AQUALUNG
27.4.2021 11:02:13 CEST | Business Wire | Press release
Aqualung , the leading global designer and manufacturer of dive and water sports gear, today announced the launch of its all new XSCAPE collection. Featuring a 100 percent neoprene-free wetsuit and a rash guard made from sustainable materials, the XSCAPE line is designed for a variety of water activities and reflects Aqualung’s commitment to innovation, ocean discovery and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005227/en/
Made with Yulex® eco-friendly natural rubber and ultra-stretch fabric, the 4/3mm XSCAPE wetsuit provides enhanced comfort for diving in warm waters or above surface activities in colder temperatures, and can be used for scuba diving, snorkeling, freediving, paddling or a variety of other water sports. The flexible and lightweight XSCAPE wetsuit, available in a red and olive design for men and a tropical-inspired print for women, connects consumers to nature and the natural materials the collection is made from. The suit also features Powertex knee pads, recycled, quick-drying fleece around the torso area to provide additional warmth and comfort, and a reusable mesh bag for storage after use or collecting trash from the beach or water.
“The XSCAPE collection continues Aqualung's legacy in innovation, and their tireless work to create the most forward thinking and eco-conscious dive company in the world,” said Aqualung global ocean ambassador Philippe Cousteau Jr., the grandson of one of Aqualung’s original founders, Captain Jacques-Yves Cousteau. “We all have the power to change the world with the choices we make, and the XSCAPE sets the new standard for wetsuits and rash guards that are stylish, functional and sustainable.”
The new collection’s long-sleeve rash guard for men and women, and matching women’s leggings, offer maximum comfort and breathability and can be used above or below the surface. All rash guards and leggings feature UV protection and are made with polyester fabric sourced from recycled plastic bottles. The entire XSCAPE line comes in plastic-free packaging with hangtags made from recycled cardboard.
“Our aim was to design the ultimate eco-friendly wetsuit that could be used for all kinds of water sports,” said Laurent Boury, Senior Vice President of Brands at Aqualung Group. “Aqualung is committed to using environmentally-friendly materials and processes whenever possible to help reduce our carbon footprint, and we made design choices to ensure the XSCAPE collection was as sustainable as possible.”
“The collection name, XSCAPE, is meant to evoke the feeling of freedom and the quest for wonder that surround exploration, travel and Aqualung’s storied history, including the first ‘aqua-lung’ created by Captain Jacques-Yves Cousteau and engineer Emile Gagnan that made underwater exploration possible,” added Boury.
The XSCAPE collection is available at authorized Aqualung retailers. Inventory may vary by region. To learn more, please visit www.aqualung.com .
About Aqualung Brand
Aqualung, part of the Aqualung Group, is the leading global designer and manufacturer of dive and water sports gear. Now available in more than 100 countries around the world, Aqualung pioneered the creation of modern diving equipment when Captain Jacques-Yves Cousteau teamed with engineer Emile Gagnan in 1943 to develop the first “aqua-lung,” making underwater exploration possible. Aqualung is committed to providing sustainable, innovative, reliable, and easy-to-use products that allow adventure seekers to enjoy responsible water exploration and continues to set the industry standard for water sports equipment in technology, comfort, safety and design. For more information, visit www.aqualung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005227/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom